About the antiemetic effectivity of granisetron in chemotherapy-induced acute emesis: A comparison of results with intravenous and oral dosing

Neoplasma

Volumn 46, Issue 2, 1999, Pages 73-79

  Lehoczky, O ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Antiemetic; Chemotherapy induced emesis; Granisetron

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; GRANISETRON; TROPISETRON;

ANTIEMETIC ACTIVITY; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONSTIPATION; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; SHORT SURVEY; VOMITING;

EID: 0033026893     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (50)

1. ANDREWS, P.L.R., BHANDARI, P., DAVEY, P.T., BINGHAM, S., MARR, H.E., BLOWER, P.R.L.: Are all 5-HT3 antagonist the same? Eur. J. Cancer, 28A, 1992, S2-S6.
2. ANDREWS, P.L.R.: The pharmacologic profile of granisetron (Kytril). Semin. Oncol. (Suppl. 1), 21, 1994, 3-9.
3. AUDHUY, B., CAPPELAERE, P., MARTIN, M., CERVANTES, A., FABBRO, M., RIVIERE, A., KHAYAT, D., BLEIBERG, H., FARALDI, M., CLAVERIE, N. on behalf of the European Dolasetron Comparative Study Group: A double-blind, randomized comparison of the antiemetic efficacy of two intravenous closes of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur. J. Cancer, 32A, 1996, 807-813.
4. BALFOUR, J.A., GOA, K.L.: Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs, 54, 1997, 273-298.
5. BLEIBERG, H.H., SPIELMAN, M., FALKSON, G., ROMAIN, D.: Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: A dose-ranging study. Clin. Ther., 17, 1995, 38-51.
6. BLIJHAM, G.H.: Does granisetron remain effective over multiple cycles? Eur. J. Cancer, 28, 1992, S17-S21.
7. BLOWER, P.: A pharmacologic profile of oral granisetron (Kytril tablets). Semin.Oncol. (Suppl. 10), 22, 1995, 3-5.
8. BONNETERE, J., HECQUET, B.: Granisetron (iv) compared with ondansetron (iv plus oral) in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. A cross-over study. Bull. Cancer (Paris), 82, 1995, 1038-1043.
9. CARMICHAEL, J., BESSEL, E.M., HARRIS, A.L., HUTCHEON, A.W., DAWES, P.J.D.K., DANIELS, S.: Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. Br. J. Cancer, 70, 1994, 1161-1164.
10. CASSIDY, J., RAINA, V., LEWIS, C., ADAMS, L., SOUKOP, M., RAPEPORT, W.G., ZUSSMAN, B.D., RANKIN, E.M., KAYE, S.B.: Pharmacocinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist. Br. J. Cancer, 55, 1988, 651-653.
11. CHEVALLIER, B. on behalf of the Granisetron Study Group: Efficacy and safety of granisetron compared with high dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur. J. Cancer (Suppl. 1), 26, 1990, 33-36.
12. CHEVALLIER, B. on behalf of the Granisetron Study Group: The control of acute cisplatin-induced emesis - a comparative study of granisetron and a combination regimen of high-dose metoclopramide and dexamethasone. Br. J. Cancer, 68, 1993, 176-180.
13. CUPPISOL, D.R., SERROU, B., CAUBEL, M.: The efficacy of granisetron as a profilactic antiemetic and intervention agent in high-dose cisplatin-induced emesis. Eur. J. Cancer (Suppl. 1), 26, 1990, S23-S27.
14. DUHEM, C., RIES, F., DICATO, M.: Side effects of antiemetics. In: Medical Management of Cancer Treatment Induced Emesis. Ed.: Dicato, A.M. London, Martin Dunitz 1998, 221-229.
15. ETTINGER, D.S.: Preventing chemotherapy-induced nausea and vomiting: An uptake and a review of emesis. Semin. Oncol., 22, 1995, S6-S18.
16. ETTINGER, D.S., EISENBERG, P.D., FITTS, D., FRIEDMAN, C., WILSON-LYNCH, K., YOCOM, K.: A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer, 78, 1996, 144-151.
17. GEBBIA, V., CANNATA, G., TESTA, A., CURTO, G., VALENZA, R., CIPOLLA, C., LATTERI, M.A., GEBBIA, N.: Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Cancer, 74, 1994, 1945-1952.
18. GEBBIA, V., TESTA, A., VALENZA, R., CANNATA, G., TIRRITO, M.L., GEBBIA, N.: Oral ganisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting in-duced by cisplatin-based chemotherapy. Cancer, 76, 1995, 1821-1829,
19. HACKING, A. on behalf of the Granisetron Study Group: Oral granisetron - simple and effective: A preliminary report. Eur. J. Cancer (Suppl. 1), 28A, 1992, S28-S32.
20. HERON, J.F., GOEDHALS, J.P., JORDAAN, J.P., CUNNINGHAM, J., CEDAR, E. on behalf of the Granisetron Study Group: Oral granisetron alone and in combination with dexamethasone: A double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. Ann. Oncol., 5, 1994, 579-584.
21. HERON, J.F.: Single-agent oral granisetron for the prevention of acute cisplatin-induced emesis: A double-blind, randomized comparison with granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone. Sem. Oncol. (Suppl. 10), 22, 1995, 24-30.
22. HESKETH, P.: Profilaxis with oral granisetron for acute emesis induced by moderately emetogenic chemotherapy. Semin. Oncol. (Suppl. 10), 22, 1995, 19-23.
23. Italian Group of Antiemetic Research: Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann. Oncol., 6, 1995, 805-810.
24. Italian Group for Antiemetic Research: Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N. Engl. J. Med., 332, 1995, 1-5.
25. JANTUNEN, I.T., MUHONEN, T.T., KATAJA, V.V., FLANDER, M.K., TEERENHOVI, L.: 5-HT3 receptor antagonists in the profilaxis of acute vomiting induced by moderately emetogenic chemotherapy - a randomized study. Eur. J. Cancer, 29A, 1993, 1669-1672.
26. KAMANABROU, D. on behalf of the Granisetron Study Group: Intravenous granisetron-establishing the optimal dose. Eur. J. Cancer (Suppl. 1), 28A, 1992, S6-S11.
27. MAISANO, R., ADAMO, V., SETTINERI, N., PERGOLIZZI, S., SCIMONE, A., ALTAVISTA, G.: Efficacy of two oral dose regimens of granisetron. Anticancer Res., 15, 1995, 2287-2290.
28. MANTOVANI, G., MACCIO, A., BIANCHI, A., CURRELI, L., GHANI, M., PROTO, E., SANTONA, M.C.: Comparison of granisetron, ondansetron and tropisetron in the profilaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: A randomized controlled trial. Cancer, 77, 1996, 941-948.
29. MARR, H.E., DAVEY, P.T., BOYLE, E.A., BLOWER, P.R.: Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Pharmacology, 48, 1994, 283-292.
30. MARTONI, A., ANGELELLI, B., GUARALDI, M., STROCCHI, E., PANNUTI, F.: An open randomized cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur. J. Cancer, 32A, 1996, 82-85.
31. MARTY, M. on behalf of the Granisetron Study Group: A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostaticinduced emesis. Eur. J. Cancer (Suppl. 1), 26, 1990, 28-32.
32. MATSUI, K., FUKUOKA, M., TAKADA, M., KUSUNOKI, Y., YANA, T., TAMURA, K., YOSHIDA, T., IIDA, K., HIRASHIMA, T., TSUKADA, H., USHIJIMA, S., MIYAWAKI, H., MASUDA, N.: Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br. J. Cancer, 73, 1996, 217-221.
33. MORROW, G.R., HICKOK, J.T., ROSENTHAL, S.N.: Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril) and tropisetron (Navoban). Cancer, 76, 1995, 343-357.
34. NAVARI, R.M., KAPLAN, H.G., GRALLA, R.J., GRUNBERG, S.M., PALMER, R., FITTS, D.: Efficacy and safety of granisetron, a selective 5-hydroxytriptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J. Clin. Oncol., 12, 1994, 2204-2210.
35. NAVARI, R., GANDARA, D., HESKETH, P., HALL, S., MAILIARD, J., RITTER, H., FRIEDMAN, C., FITTS, D. on behalf of the Granisteron Study Group: Comparative clinical trial of granisetron and ondansetron in the profilaxis of cisplatin-induced emesis. J. Clin. Oncol., 13, 1995, 1242-1248.
36. NOBLE, A., BREMER, K., GOEDHALS, L., CUPISSOL, D., DILLY, S.G. on behalf of the Granisetron Study Group: A double-blind, randomized, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assesment of efficacy, safety and patient preference. Eur. J. Cancer, 30A, 1994, 1083-1088.
37. PINTENS, H.: Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: A summary. Cancer Treat. Rev., 17, 1990, 307-310.
38. RIVIERE, A. on behalf of the Granisetron Study Group: Dose finding study of granisteron in patients receiving high-dose cisplatin chemotherapy. Br. J. Cancer, 69, 1994, 967-971.
39. RUFF, P., PASKA, W., GOEDHALS, L., POUILLART, P., RIVIERE, A., VOROBIOF, D., BLOCH, B., JONES, A., MARTIN, C., BRUNET, R., BUTCHER, M., FÖRSTER, J., MCQUADE, B. on behalf of the Granisetron Study Group: Ondansetron compared with granisetron in the profilaxis of cisplatin-induced acute emesis: A multicenter double-blind, randomized, paralell-group study. Oncology, 5, 1994, 113-118.
40. SISMONDI, P., DANESE, S., GIARDINA, G., GUERCIO, E., RICHIARDI, G., CARNINO, F., FERRARIS, C., LISSONI, A., INGANNI, P., MAGGI, R., BOCCARDO, E., BARBIERI, P.: Antiemetic efficacy of granisetron in patients with gynecological malignancies. Anticancer Drugs, 8, 1997, 225-230.
41. SMITH, I.E. on behalf of the Granisetron Study Group: A comparison of two dose level of granisetron in patients receiving high-dose cisplatin. Eur. J. Cancer (Suppl. 1), 26, 1990, 19-23.
42. SMITH, I.E. on behalf of the Granisetron Study Group: A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J. Cancer Res. Clin. Oncol., 119, 1993, 350-354.
43. SMITH, D.B., NEWLANDS, E.S., RUSTIN, G.J., BEGENT, R.H., HOWELLS, N., MCQUADE, B., BAGSHAWE, K.D.: Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic profilaxis during cisplatin-containing chemotherapy. Lancet, 338, 1991, 487-490.
44. SOUKOP, M. on behalf of the Granisetron Study Group: A comparison of two dose level of granisetron in patients receiving high-dose cisplatin. Eur. J. Cancer (Suppl. 1), 26, 1990, 15-19.
45. TERREY, J.P., AAPRO, M.S. on behalf of the Granisetron Study Group: The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur. J. Clin. Res., 8, 1996, 281-288.
46. TSUKUDA, M., FURUKAWA, S., KOKATSU, T., ENOMOTO, H., KUBOTA, A., FURUKAWA, M.: Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloridc for profilactic treatment of emesis induced by cisplatin chemotherapy. Eur. J. Cancer, 31A, 1995, 1647-1649.
47. UPWARD, J.W., ARNOLD, B.D.C., LINK, C., PIERCE, D.M., ALLEN, A., TASKER, T.C.G.: The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur. J. Cancer, 26, 1990, S12-S15.
48. VEYRAT-FOLLET, C., FARIOTTI, R., PALMER, J.L.: Physiology of chemotherapy-induced emesis and antiemetic therapy. Drugs, 53, 1997, 206-234.
49. WARR, D., WILLAN, A., FINE, S., WILSON, K., DAVIS, A., ERLICHMAN, C., RUSTHOVEN, J., LOFTERS, W., OSOBA, D., LABERGE, F., LATREILLE, J., PATER, J.: Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J. Natl. Cancer Inst., 83, 1991, 1169-1173.
50. WUNGAARDEN, I. VAN, TULP, M.TH.M., SOUDIJN, W.: The concept of selectivity in 5-HT receptor research. Eur. J. Pharmacol., 188, 1990, 301-312.